GYNECOLOGIC CANCERS

A new study reveals that pembrolizumab and bevacizumab offer a promising, less toxic treatment for recurrent ovarian cancer, especially the clear cell subtype.

FDA accepts relacorilant and nab-paclitaxel for platinum-resistant ovarian cancer, showing promising survival benefits in recent trials.

Researchers explore DNA methylation patterns for early ovarian cancer detection, aiming to improve survival rates through innovative blood tests.

FDA breakthrough therapy designation granted for rinatabart sesutecan in endometrial cancer, based on encouraging data from a phase 1/2 trial.

Incorporating molecular classification into preoperative staging for endometrial cancer improved risk stratification in patients with high-risk endometrial cancer.

A study compares second-look laparoscopy and circulating tumor DNA (ctDNA) to detect residual ovarian cancer and predict patient outcomes.

An MD Anderson team led by Amir Jazaeri, MD, takes a pioneering approach to finding residual ovarian cancer cells.

Research reveals innovative methods for detecting minimal residual disease in ovarian cancer, enhancing prognosis and paving the way for targeted therapies.

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data from recent clinical trials.

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 diabetes compared to other treatments.

Patient dosing has continued to successfully escalate in an early-phase trial of a novel FSHR-targeting CAR T-cell therapy in ovarian cancer.

Fertility preservation becomes crucial for reproductive-age cancer patients, emphasizing timely intervention and collaboration between oncology and reproductive specialists.

A significant number of patients with ovarian cancer miss preventive salpingectomy opportunities during unrelated surgeries.

A phase 3 trial showed that alpelisib plus olaparib did not reduce the risk of progression or death in relapsed/refractory ovarian cancer.

A promising allogeneic CAR T therapy has shown the potential to succeed in ovarian cancer where standard CAR-T treatments have failed.

The results support the potential for treatment de-escalation after hysterectomy for women with early-stage, intermediate-risk cervical cancer.

Katherine McDaniel, MD, a reproductive endocrinologist, discusses the key takeaways for oncologists treating patients of reproductive age.

Katherine McDaniel, MD, discusses the barriers to fertility preservation access for patients diagnosed with cancer.

Katherine McDaniel, MD, discusses fertility preservation options for patients facing a cancer diagnosis and how the landscape has changed over the past two decades.

A recent study characterized the expression of ADC targets across ovarian cancer histotypes. Findings suggest histotype-specific ADC utility, particularly for B7-H4 target.

A recent study highlights disparities in federal cancer funding, revealing that high-mortality cancers like lung and liver are significantly underfunded.

Tislelizumab combined with chemotherapy shows promising antitumor activity in advanced cervical cancer, achieving high response rates and manageable safety profiles.

Emiltatug ledadotin shows promising antitumor activity in various cancers, with manageable safety, highlighting its potential in targeted therapy advancements.

Emiltatug ledadotin demonstrated promising antitumor activity and a manageable safety profile in a phase 1 dose-escalation trial.

A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, enhancing standard chemotherapy outcomes.